Table 3

 Treatment regimen employed

Regimen (evaluable patients)Patients (n)
*Cyclophosphamide was given at 4 g/m2 either in one injection or in two daily successive injections of 2 g/m2 according to the centres; †granulocyte-colony stimulating factor (G-CSF) used either rHu G-CSF (Lenograstim†, Aventis and Chugai Pharma, France) or G-CSF (Filgrastim†, AMGEN).
ATG, antithymocyte globulins; TLI, total lymphoid irradiation.
Priming (n = 56)
Cyclophosphamide* alone2
G-CSF alone6
PBSC selection (n = 55)
No selection7
CD34+ selection alone38
CD34+ and other monoclonal antibody9
CAMPATH 1 alone1
Conditioning (n = 57)
Cyclophosphamide 150–200 mg/kg35
Cyclophosphamide 120 mg/kg+ATG+TLI1
Cyclophosphamide 200 mg/kg+ATG12
Cyclophosphamide 200 mg/kg+CAMPATH-13
Cyclophosphamide 200 mg/kg+TLI1
Other chemotherapy4